You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》藥明巨諾(02126.HK)今日起招股 入場費12,019.92元
阿思達克 10-22 09:27
由藥明康德(02359.HK)及美國醫藥研發平台Juno共同投資、內地臨床及臨床前階段細胞治療公司藥明巨諾(02126.HK)公布招股詳情,計劃發行9,769.2萬股,當中約10%在港公開發售,招股價介乎20至23.8元,一手500股,入場費12,019.92元;由今日(22日)至下周三(28日)公開招股,預計11月3日掛牌上市。高盛及瑞銀為聯席保薦人。

該股引入10名基石投資者,共認購1.5億美元股份,包括Rock Springs Capital、橡樹資本管理公司等各認購2,000萬美元;高瓴基金、太平資產管理等各認購1,000萬美元。

以招股價中位數21.9元計,公司預計集資淨額為20.18億元,當中30%將用於有關relma-cel的研發活動;10%用於建立專門的內部銷售與營銷團隊將relmacel推廣至中國各地;6%用於有關JWCAR129的研發活動;28%用於有關其他臨床前候選產品;4%用於透過行使Acepodia選擇權獲得Acepodia許可;12%將用於新潛在收購及引進授權機會;餘下10%為營運資金及一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account